Progesterone therapy, endothelial function and cardiovascular risk factors: A 3-month randomized, placebo-controlled trial in healthy early postmenopausal women

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Prior, Jerilynn C ^a   Elliott, Thomas G ^a   Norman, Eric ^a   Stajic, Vesna ^a   Hitchcock, Christine L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PROGESTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD CLOTTING; BODY MASS; BODY WEIGHT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM; FEMALE; FRAMINGHAM GENERAL CARDIOVASCULAR RISK PROFILE SCORE; HEART PROTECTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LIPID COMPOSITION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NIGHT SWEAT; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RESTING HEART RATE; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VEIN OCCLUSION PLETHYSMOGRAPHY; WAIST CIRCUMFERENCE;

BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOREARM; HUMANS; MIDDLE AGED; PLETHYSMOGRAPHY; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84898614110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084698     Document Type: Article

References (36)

1. Hitchcock CL, Prior JC (2012) Oral Micronized Progesterone for Vasomotor Symptoms in Healthy Postmenopausal Women - a placebo-controlled randomized trial. Menopause 19: 886-893.
2. Grady D, Sawaya GF (2005) Discontinuation of postmenopausal hormone therapy. Am J Med 118 Suppl 12B: 163-165.
3. Menon U, Burnell M, Sharma A, Gentry-Maharaj A, Fraser L, et al. (2007) Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 14: 462-467.
4. Lawton B, Rose S, McLeod D, Dowell A (2003) Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 327: 845-846. (Pubitemid 37271698)
5. Nath A, Sitruk-Ware R (2009) Different cardiovascular effects of progestins according to structure and activity. Climacteric 12 Suppl 1: 96-101.
6. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273: 199-208.
7. Hitchcock CL, Elliott TG, Norman EG, Stajic V, Teede H, et al. (2012) Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women. Menopause 19: 1208-1214.
8. Turgeon JL, McDonnell DP, Martin KA, Wise PM (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304: 1269-1273. (Pubitemid 38697412)
9. Tunstall-Pedoe H (1998) Myth and paradox of coronary risk and the menopause. Lancet 351: 1425-1427.
10. Kharazmi E, Dossus L, Rohrmann S, Kaaks R (2010) Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart doi: 10.1136/hrt.2010.202226: 1-6.
11. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335: 453-461. (Pubitemid 26269944)
12. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712. (Pubitemid 38489892)
13. Hulley S, Bush T, Furberg C, Herrington D, Riggs B, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 280: 605-613. (Pubitemid 28502636)
14. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in health postmenopausal women: prinicple results from the Women's Health Initiative Randomized Control trial. JAMA 288: 321-333.
15. Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323: 1221-1227. (Pubitemid 20366526)
16. Bedford JL, Prior JC, Barr SI (2010) A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol and change in bone density over two years in healthy young women. JCEM 95: 3291-3299.
17. Waugh EJ, Polivy J, Ridout R, Hawker GA (2007) A prospective investigation of the relations among cognitive dietary restraint, subclinical ovulatory disturbances, physical activity, and bone mass in healthy young women. Am J Clin Nutr 86: 1791-1801. (Pubitemid 350232197)
18. Arck PC, Rucke M, Rose M, Szekeres-Bartho J, Douglas AJ, et al. (2008) Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 17: 101-113.
19. Gorgels WJ, Graaf Y, Blankenstein MA, Collette HJ, Erkelens DW, et al. (1997) Urinary sex hormone excretions in premenopausal women and coronary heart disease risk: a nested case-referent study in the DOM-cohort. J Clin Epidemiol 50: 275-281. (Pubitemid 27165704)
20. Kaplan JR, Adams MR, Clarkson TB, Koritnik DR (1984) Psychological influences on female 'protection' among cynomolgus macaques. Atherosclerosis 53: 283-295. (Pubitemid 15194151)
21. Adams MR, Kaplan JF, Koritnik DR (1985) Ovariectomy, social status, and atherosclerosis in cynomolgus monkeys. Arteriosclerosis 5: 192-200. (Pubitemid 15145376)
22. Rylance PB, Brincat M, Lafferty K, De Trafford JC, Brincat S, et al. (1985) Natural progesterone and antihypertensive action. Br Med J 290: 13-14. (Pubitemid 15075974)
23. Mather KJ, Norman EG, Prior JC, Elliott TG (2000) Preserved forearm endothelial responses with acute exposure to progesterone: a randomized crossover trial of 17-b estradiol, progesterone, and 17-b estradiol with progesterone in healthy menopausal women. J Clin Endocrinol Metab 85: 4644-4649. (Pubitemid 32157647)
24. Battistella E, Kalyan S, Prior J (2010) Evaluation of Successful Methods and Costs Associated with Recruiting 600 Healthy Women Volunteers to a Study of Ovulation. J Women's Health 19: 1519-1524.
25. Kalyan S, Hitchcock CL, Sirrs S, Pudek M, Prior JC (2010) Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. Pharmacotherapy 30: 442-452.
26. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743-753. (Pubitemid 351640675)
27. Simon JA, Shangold MM, Andrews MC, Buster JC, Hodgen GD (1992) Micronized progesterone therapy: the importance of route of administration and pharmacokinetics on clinical outcome. J Contracept Fertil Sex 20: 13-18.
28. Schussler P, Kluge M, Yassouridis A, Dresler M, Held K, et al. (2008) Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocr 33: 1124-1131.
29. Friess E, Tagaya H, Trachsel L, Holsboer F, Rupprecht R (1997) Progesterone-induced changes in sleep in male subjects. Am J Physiol 272: E885-E891.
30. Sathi P, Kalyan S, Hitchcock CL, Pudek M, Prior JC (2012) Progesterone Therapy increases Free Thyroxine Levels- data from a randomized placebo-controlled 12-week hot flush trial. Clin Endocrinol (Oxf). doi: 10.1111/cen.12128
31. Ikram Z, Dulipsingh L, Prestwood KM (1999) Lack of effect of short-term micronized progesterone on bone turnover in postmenopausal women. J Womens Health Gend Based Med 8: 973-978. (Pubitemid 29501942)
32. Francis GA (2010) The complexity of HDL. Biochim Biophys Acta 1801: 1286-1293.
33. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267.
34. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843. (Pubitemid 30165206)
35. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, et al. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 25: 567-579.
36. Canonico M, Oger E, Plu-Bureau, Conard J, Meyer G, et al. (2007) Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840-845. (Pubitemid 46294724)